Company intelligence / Profile preview
StarWise Therapeutics
Cambridge, Massachusetts, United Statesstarwisetx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
StarWise Therapeutics is a pre-clinical stage biotechnology company focused on developing next-generation RNA interference (RNAi) therapies. The company's primary mission is to enable the delivery of small interfering RNA (siRNA) to tissues outside of the liver, such as the central nervous system, lungs, and muscle. Leveraging a proprietary delivery platform, StarWise aims to expand the therapeutic potential of RNAi to a wider array of genetic and chronic diseases. The leadership team includes veterans from Alnylam Pharmaceuticals and Third Rock Ventures, bringing significant expertise in RNA medicine and drug development.
- Therapeutic areas
- RheumatologyPulmonologyNeurology
- Modalities
- Small interfering RNARNA therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on StarWise Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on StarWise Therapeutics.